Routine clinical chemistries as improved determinates of prognosis for patients with metastatic cancer of the stomach.
Pretreatment total serum protein of less than 6 g%, serum glumatic oxaloacetic transaminase (SGOT) greater than 40 mU/ml or a total serum bilirubin greater than 0.6 mg% predicted a bad prognosis for patients with metastatic gastric cancer. If two of these objective laboratory tests predicted a good prognosis, partially nonambulatory patients lived an additional 20 weeks (median survival 27.9 vs 8.7, p less than 0.001) and patients with no clinically recognized liver metastases lived an additional 22 weeks (median survival 34.2 vs. 12.4, p less than 0.001). Patients with liver metastases lived an additional 11 weeks (median survival 20.9 vs. 9.6, p less than 0.001). These objective laboratory tests improve the assessment of patients in clinical trials. The model corrected a false assessment of a poor prognosis for 38% of all patients and 64% of patients with liver metastases.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000556:secondary; D011336:Probability; D011379:Prognosis; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000097:blood* / Q000188:drug therapy
D000970:Antineoplastic Agents; D001798:Blood Proteins; D001219:Aspartate Aminotransferases; D001663:Bilirubin